Salwa A Elgebaly from Vienna, VA, age 74

Name / Title

Company / Classification

Phones & Addresses

Salwa A. Elgebaly
Executive Director

Nour Heart Inc
Therapeutic Biotech Co

2127 Bch Vlg Ct, Annapolis, MD 21403

Mitochondrial Markers Of Ischemia
view source
US Patent:

7662571, Feb 16, 2010
Filed:

Jul 13, 2006
Appl. No.:

11/486741
Inventors:

Salwa A. Elgebaly - Edgewater MD, US
Elliott Schiffmann - Chevy Chase MD, US
Assignee:

Nourheart Inc. - Edgewood MD
International Classification:

G01N 33/53
US Classification:

435 71, 435 72, 436517
Abstract:

Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Methods To Prevent And Treat Diseases
view source
US Patent:

8288350, Oct 16, 2012
Filed:

May 19, 2011
Appl. No.:

13/111571
Inventors:

Salwa A. Elgebaly - Annapolis MD, US
Elliott Schiffmann - Chevy Chase MD, US
Assignee:

Nour Heart, Inc. - Germantown MD
International Classification:

A61K 38/04
A61K 38/13
A61K 38/00
US Classification:

514 214, 514 11, 514 23, 514 122, 514 183, 514 205
Abstract:

Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Nourexin-4 Nano-Lipid Emulsions
view source
US Patent:

8333987, Dec 18, 2012
Filed:

Sep 30, 2009
Appl. No.:

12/570307
Inventors:

Salwa Elgebaly - Edgewater MD, US
Elliott Schiffmann - Chevy Chase MD, US
Tamer Elbayoumi - Peoria AZ, US
International Classification:

A61K 9/127
G01N 33/53
C12Q 1/70
A61K 31/197
A61P 37/04
A61P 31/14
A61P 31/04
US Classification:

424450, 435 721, 435 5, 514565
Abstract:

The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.

Diagnostic Marker
view source
US Patent:

20060063199, Mar 23, 2006
Filed:

Nov 23, 2004
Appl. No.:

10/994521
Inventors:

Salwa Elgebaly - Edgewater MD, US
Paul Sheard - Great Doddington, GB
International Classification:

G01N 33/53
US Classification:

435007100
Abstract:

An inflammatory peptide can be a marker for cardiac ischemia.

Mitochondrial Markers Of Ischemia
view source
US Patent:

20070122847, May 31, 2007
Filed:

Oct 26, 2006
Appl. No.:

11/586927
Inventors:

Salwa Elgebaly - Edgewater MD, US
Elliot Schiffman - Chevy Chase MD, US
Assignee:

Nour Heart, Inc. - Edgewater MD
International Classification:

G01N 33/53
G01N 33/567
US Classification:

435007100, 435007200
Abstract:

Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Methods To Prevent And Treat Diseases
view source
US Patent:

20080008694, Jan 10, 2008
Filed:

Mar 29, 2007
Appl. No.:

11/693289
Inventors:

Salwa Elgebaly - Edgewater MD, US
Elliott Schiffmann - Chevy Chase MD, US
International Classification:

A61K 31/195
A61K 38/04
A61K 38/43
A61K 39/395
A61P 29/00
US Classification:

424094100, 424130100, 514016000, 514565000
Abstract:

This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Phosphagen Synthesis
view source
US Patent:

20080242639, Oct 2, 2008
Filed:

Dec 29, 2005
Appl. No.:

11/794589
Inventors:

Farghaly Ahmed - Alexandria, EG
Salwa A. Elgebaly - Edgewater MD, US
International Classification:

C07F 9/6506
C07D 233/46
A61K 31/675
A61P 9/10
A61K 31/4168
US Classification:

514 94, 5483325, 514392, 548111
Abstract:

Cyclocreatine phosphate can be prepared in large quantities from inexpensive starting materials to afford a stable product.

view source

Salwa A Elgebaly